Sun Pharma specialty drug Tildrakizumab makes it to China's reimbursement list

The inclusion of tildrakizumab injection in NRDL will further boost Sun Pharma commercialisation efforts globally. NRDL is a list of drugs fully or partially reimbursed by the national basic health insurance in China covering 96% of the population or more than 1.36 billion people.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W6zVxEK
via IFTTT